GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

BeOne Medicines 688235.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

285.00

+2.30%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥36.84bn

FY2016FY2025

Net income

CN¥1.98bn

FY2016FY2025

Free cash flow

CN¥6.49bn

FY2016FY2025

Shareholders' equity

CN¥29.23bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥36.84bnCN¥25.57bnCN¥16.50bnCN¥9.50bnCN¥7.89bnCN¥308.9mCN¥2.87bnCN¥1.33bnCN¥1.60bnCN¥7.2m
Gross profitCN¥31.42bnCN¥21.58bnCN¥13.95bnCN¥7.58bnCN¥6.79bn−CN¥1.06bn−CN¥3.83bn−CN¥3.42bn−CN¥238.9m−CN¥650.6m
Research and developmentCN¥14.30bnCN¥13.11bnCN¥11.93bnCN¥11.01bnCN¥9.79bnCN¥1.29bnCN¥6.22bnCN¥4.56bnCN¥1.80bnCN¥657.8m
Operating incomeCN¥3.08bn−CN¥3.81bn−CN¥8.10bn−CN¥12.01bn−CN¥9.65bn−CN¥1.66bn−CN¥6.44bn−CN¥4.74bn−CN¥660.6m−CN¥785.4m
Net incomeCN¥1.98bn−CN¥4.33bn−CN¥5.92bn−CN¥13.44bn−CN¥9.78bn−CN¥1.62bn−CN¥6.36bn−CN¥4.52bn−CN¥624.7m−CN¥799.9m
Diluted earnings per share1.32-40.71-56.84-129.57-102.93-17.89-104.88-76.13-13.76-22.43

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥55.18bnCN¥39.73bnCN¥38.95bnCN¥42.80bnCN¥58.01bnCN¥5.60bnCN¥10.82bnCN¥15.09bnCN¥7.02bnCN¥2.72bn
Cash and short-term investmentsCN¥30.76bnCN¥17.63bnCN¥21.30bnCN¥30.43bnCN¥44.45bnCN¥4.66bnCN¥6.61bnCN¥12.14bnCN¥5.62bnCN¥2.47bn
Total liabilitiesCN¥25.76bnCN¥17.37bnCN¥15.22bnCN¥13.39bnCN¥16.12bnCN¥1.73bnCN¥4.25bnCN¥3.33bnCN¥2.43bnCN¥2.72bn
Debt—CN¥7.81bnCN¥6.60bnCN¥4.15bnCN¥4.34bnCN¥3.59bnCN¥836.5mCN¥340.4m——
Shareholders' equityCN¥29.23bnCN¥22.36bnCN¥23.73bnCN¥29.41bnCN¥41.89bnCN¥3.87bnCN¥6.56bnCN¥11.77bnCN¥4.59bnCN¥2.37bn
Shares outstanding1,500m106m104m104m95m91m61m59m45m36m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥7.77bn−CN¥943.6m−CN¥7.77bn−CN¥10.04bn−CN¥8.71bn−CN¥1.28bn−CN¥5.03bn−CN¥3.67bnCN¥85.6m−CN¥600.6m
Capital spending−CN¥1.28bn−CN¥3.55bn−CN¥4.00bn−CN¥3.15bn−CN¥2.11bn−CN¥229.0m−CN¥1.06bn−CN¥945.0m−CN¥394.0m−CN¥157.7m
Free cash flowCN¥6.49bn−CN¥4.49bn−CN¥11.77bn−CN¥13.19bn−CN¥10.83bn−CN¥1.51bn−CN¥6.10bn−CN¥4.62bn−CN¥308.5m−CN¥758.3m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥11.44bnCN¥10.15bnCN¥10.19bnCN¥9.48bnCN¥8.83bnCN¥7.50bnCN¥7.97bnCN¥7.02bn
Gross profitCN¥10.27bnCN¥9.03bnCN¥9.01bnCN¥8.16bnCN¥7.72bnCN¥6.39bnCN¥6.81bnCN¥5.85bn
Operating incomeCN¥2.18bnCN¥1.68bnCN¥1.26bnCN¥1.09bnCN¥589.7mCN¥74.5m−CN¥677.1m−CN¥789.6m
Net incomeCN¥1.59bnCN¥1.53bnCN¥452.3mCN¥837.6mCN¥632.8mCN¥8.5m−CN¥937.3m−CN¥1.03bn
Diluted earnings per share1.061.020.300.560.420.01-8.82-9.72
Cash from operationsCN¥3.10bnCN¥1.35bnCN¥2.85bnCN¥2.70bnCN¥1.77bnCN¥295.0mCN¥504.0mCN¥1.26bn
Capital spending−CN¥322.0m−CN¥273.0m−CN¥254.0m−CN¥322.0m−CN¥428.0m−CN¥781.0m−CN¥620.0m−CN¥896.0m
Free cash flowCN¥2.78bnCN¥1.08bnCN¥2.60bnCN¥2.38bnCN¥1.34bn−CN¥486.0m−CN¥116.0mCN¥367.0m
Total assetsCN¥61.56bnCN¥57.39bnCN¥55.18bnCN¥51.21bnCN¥42.26bnCN¥39.19bnCN¥39.73bnCN¥39.12bn
Cash and short-term investments——CN¥30.76bnCN¥27.09bnCN¥18.49bnCN¥16.88bnCN¥17.63bnCN¥18.13bn
DebtCN¥5.92bnCN¥6.46bnCN¥6.98bnCN¥6.50bnCN¥6.52bnCN¥6.32bnCN¥6.95bnCN¥7.17bn
Shareholders' equityCN¥34.72bnCN¥31.94bnCN¥29.23bnCN¥27.71bnCN¥25.30bnCN¥23.48bnCN¥22.36bnCN¥23.05bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue57.1%160.2%90.3%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin84.9%84.3%83.1%70.1%
Operating margin-1.2%-23.6%-33.3%-44.1%
Net margin-3.8%-24.6%-34.3%-44.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings203.6-4.0-2.5-1.0-1.4
Price to sales10.90.70.91.41.7

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.